Stand up for Your Health With a Sit-stand Desk

Sponsor
Medical College of Wisconsin (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05585190
Collaborator
(none)
200
1
3
60
3.3

Study Details

Study Description

Brief Summary

More than 84 million - or 1 out of every 3 U.S. adults - have prediabetes, a condition that if not treated often leads to type 2 diabetes within five years. Average medical expenditures among diabetics are about 2.3 times higher than expenditures for people without diabetes. Physical inactivity and elevated body mass index (BMI) are major risk factors for the disease. Sedentary behavior is becoming increasingly prevalent with the growth of a 'work from home' culture, most recently driven by the COVID-19 pandemic. Cross-sectional epidemiologic data report significant associations between high amounts of sedentary (sitting) time and prevalent cardiovascular disease and diabetes. In our pilot study of 15 subjects with sedentary office jobs, 6 months of sit-stand desk use resulted in a 23% improvement in insulin resistance, most substantial in those who decreased daily sitting by over 90 minutes/day. Additional improvements in vascular endothelial function and triglyceride levels were seen without any change in exercise activity, step counts, or body weight. These findings not only corroborate epidemiologic findings on this topic but suggest causality and warrant a randomized control trial.

The investigators hypothesize that adult subjects at-risk for diabetes will improve insulin sensitivity, metabolic and vascular (endothelial) health with a sit-stand desk intervention at work (whether in the office or at home), in the context of a randomized, controlled trial. The investigators will randomize 198 sedentary office workers with a BMI≥25 at risk for type 2 diabetes mellitus in a 1:1:1 ratio of three groups: (a) sit-stand desk intervention targeting 2 hours standing per day; (b) sit-stand desk intervention targeting 3 hours standing per day; or (c) control arm over 6 months. The block randomization design will allow for important dose-response analyses.

The investigators will objectively quantify standing time, sedentary time, sedentary bouts, daily steps, and exercise activity times using a compact and re-usable accelerometer that adheres to the subject's thigh. This will provide objective assessments of activity levels and sedentary times for 7 full days each at baseline, 3 and 6 months. The device is equipped with an inclinometer to classify posture (sitting verses standing).

Condition or Disease Intervention/Treatment Phase
  • Other: Control
  • Other: 2-Hour Stand Group
  • Other: 3-Hour Stand Group
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Stand Up for Your Health: A Randomized Study
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2027
Anticipated Study Completion Date :
Dec 31, 2027

Arms and Interventions

Arm Intervention/Treatment
Other: Control

Subjects will not receive a sit/stand desk for the duration of the study and will be asked to follow their normal work day routine.

Other: Control
No intervention.

Active Comparator: 2-Hour Group

Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 2 hours each work day.

Other: 2-Hour Stand Group
Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 2 hours each work day.

Active Comparator: 3-Hour Group

Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 3 hours each work day.

Other: 3-Hour Stand Group
Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 3 hours each work day.

Outcome Measures

Primary Outcome Measures

  1. Insulin sensitivity (HOMA-IR) [baseline to 6 months and baseline to 3 months changes]

    Determine if use of a sit-stand desk improves insulin sensitivity and ascertain if there is a dose-response relationship with changes in sedentary time.

Secondary Outcome Measures

  1. HbA1c, fasting glucose, fasting insulin [baseline to 6 months and baseline to 3 months changes]

    Determine if use of a sit-stand desk improves insulin sensitivity.

  2. metabolic syndrome and metabolic syndrome severity (MetS) score [baseline to 6 months and baseline to 3 months changes]

    Determine if use of a sit-stand desk at work improves metabolic health, as assessed by number of (NCEP ATP III) metabolic syndrome criteria and MetS severity score, in sedentary office workers at-risk for type 2 diabetes mellitus.

  3. fasting triglycerides, very low density lipoprotein (VLDL) [baseline to 6 months and baseline to 3 months changes]

    To quantify changes in serum fasting triglyceride levels and triglyceride-rich, remnant lipoproteins with the sit-stand desk (compared to no desk), while accounting for dietary intake.

  4. vascular endothelial function (superficial femoral and brachial arteries) and resilience to a high-glucose load [baseline to 6 months and baseline to 3 months changes]

    To measure the changes in vascular endothelial function with the sit-stand desk compared to control.

Other Outcome Measures

  1. free fatty acids [baseline to 6 months and baseline to 3 months changes]

    Measure the impact of the sit-stand desk on changes in fasting serum free fatty acids (FFAs) and correlate with changes in endothelial function.

  2. Acceptability Questionnaire [6 months]

    Includes questions on ease of use, comfort, perceived work productivity, and musculoskeletal discomforts related to use of the sit-stand desk. Higher scores are more favorable.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Overweight or obese (body mass index > 25 kg/m2)

  2. An employee of the Medical College of Wisconsin with "sedentary" jobs, defined as spending at least 75% of their (8 hours or more) workday sitting at a desk (at home or in an office)

  3. Defined as "at-risk" for diabetes, defined as either:

  4. Prediabetes (HbA1c of 5.7% to 6.4%) or a fasting glucose of 100 to 125 mg/dL

  5. Having one or more additional risk factors: (beyond BMI>25)

  • Age 45 years or older

  • Family history of diabetes mellitus in a first-degree relative

  • Physical inactivity (no structured exercise activity)

  • History of gestational diabetes, hypertension, or dyslipidemia

  • African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, Native Hawaiian, or Pacific Islander ethnicity

Exclusion Criteria:
  1. Established cardiovascular disease (myocardial infarction, coronary stent, coronary artery bypass grafting, cardiac transplant, or angina)

  2. Established congestive heart failure or cardiomyopathy

  3. Established peripheral vascular disease

  4. Established diabetes (HbA1c ≥ 6.5% or on diabetes medications or insulin)

  5. Chronic musculoskeletal disorders involving the lower extremities, such as arthritis of the knees or hips, or regular use of ambulatory assist devices such as a walker or cane

  6. Neuropathy of any etiology

  7. Positional syncope or history of orthostasis

  8. Less than 4 days/week at any single office (or work-from-home) location.

  9. Current use of a standing desk for work

  10. Tobacco use within the previous 12 months

  11. Current illicit drug use or excessive alcohol use (defined as more than 14 drinks/week for women, more than 28 drinks/week for men)

  12. Steroid use ≥21 days/year

  13. Fasting triglyceride level ≥ 500 mg/dL

  14. Thyroid disease

  15. Uncontrolled or untreated hypertension(>150/90 mm Hg)

  16. Pregnant or lactating (or plans to become pregnant in the next 6 months)

  17. LDL cholesterol ≥ 190mg/dL

  18. Currently enrolled or plans to diet or join a weight loss program over the next 6 months.

  19. Non-English speaker

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical College of Wisconsin Milwaukee Wisconsin United States 53226

Sponsors and Collaborators

  • Medical College of Wisconsin

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jacquelyn Kulinski, Principal Investigator, Medical College of Wisconsin
ClinicalTrials.gov Identifier:
NCT05585190
Other Study ID Numbers:
  • 44431
First Posted:
Oct 18, 2022
Last Update Posted:
Oct 20, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jacquelyn Kulinski, Principal Investigator, Medical College of Wisconsin
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 20, 2022